Zevra Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
Zevra Therapeutics, Inc. (ZVRA) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of -0.55% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2025-03-12
- Zevra Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2024 was -0.55%.
- Zevra Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2023 was -0.20%.
- Zevra Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2022 was -1.09%.
- Zevra Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2021 was -2.68%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month as first filed |
|---|---|---|
| 2024-12-31 | -0.55% 10-K · filed 2025-03-12 | |
| 2023-12-31 | -0.20% 10-K · filed 2025-03-12 | |
| 2022-12-31 | -1.09% 10-K · filed 2024-04-01 | -0.69% 10-K · filed 2023-03-07 |
| 2021-12-31 | -2.68% 10-K · filed 2023-03-07 | |
| 2020-12-31 | -2.18% 10-K · filed 2022-03-31 | |
| 2019-12-31 | -1.10% 10-K · filed 2020-02-28 | |
| 2018-12-31 | -0.63% 10-K · filed 2020-02-28 | |
| 2017-12-31 | -1.03% 10-K · filed 2019-03-01 | |
| 2016-12-31 | -12.71% 10-K · filed 2018-03-30 | |
| 2015-12-31 | -1.28% 10-K · filed 2018-03-30 | 1.28% 10-K · filed 2016-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |